Scoring Criteria		Scoring Rubric					
		No Go	0	1	2	3	4
TRIAGE & MUST-HAVE	**Safety**	Not approved for any other disease indication in proposed formulation	Previously approved for other disease indication, but lacks safety data in proposed dose			Adequate safety profile with suitable benefit/risk profile (i.e., with safety warning that needs to be adjudicated)	Strong safety profile - previously approved for other indication(s) in broad patient populations with adequate amount of historical safety data
	Route of Administration	Difficult to administer (e.g., IV) or store (e.g., requiring specialized equipment)				Moderately difficult to administer (e.g., inhaled, intranasal, SubQ) and store (e.g., refrigerated / 4°C)	Easy to administer (e.g., oral, metered-dose inhaler) and store (e.g., room temp)
MUST-HAVE	**Rationale for MOA to be Relevant to COVID-19**		Unknown	Weak	Moderate	Strong - reasonable rationale for use with COVID-19 and appropriate for outpatient setting	
	Relevant Clinical Trial Data for Early COVID-19	*Note: A wholistic approach is taken to evaluate the range of relevant clinical trial data available; rubrics outlined here are proposed for guidance purposes only (see figure legend).*					
		Majority of clinical data shows no effect in outpatient setting	No data from outpatient trials	Data from one or more outpatient trials in **mechanistically relevant disease** with promising initial results	Mixed/inconclusive results from **outpatient uncontrolled trials and/or RCTs** in SARS CoV-2 or related virus	Overall promising initial results from **uncontrolled outpatient trials** for SARS CoV-2 or related virus	Overall highly promising initial results including data from **one or more outpatient RCTs** for SARS CoV-2 or related virus
	Real World Evidence (RWE)		No evidence of efficacy from use in the clinical setting / no data to judge	Valid data from **one** RWE case study suggesting clinical efficacy	Valid data from **multiple** RWE case series suggesting clinical efficacy		
	Drug-drug Interaction (DDI)	Major concern (clinically significant DDIs)	Insufficient/no data to judge	Minor concern/manageable drug interactions	None		
NICE-TO-HAVE	**Preclinical Data**		No preclinical data/shows no effect	In vivo data in appropriate animal model			
	PK/PD		No PK/PD data/insufficient plasma levels	Sufficient plasma and/or tissue levels			
	Need for Scientific Clarity		No expressed interest from the public/scientific community		Significant interest from the public/scientific community, with no current plans to investigate in an adequately powered trial		

Note: Availability / scalability will be assessed after prioritization of any agent before official entry into the trial